Generation of polyclonal antibody with high avidity to rosuvastatin and its use in development of highly sensitive ELISA for determination of rosuvastatin in plasma by Darwish, Ibrahim A et al.
RESEARCH ARTICLE Open Access
Generation of polyclonal antibody with high
avidity to rosuvastatin and its use in
development of highly sensitive ELISA for
determination of rosuvastatin in plasma
Ibrahim A Darwish
*, Abdul-Rahman M Al-Obaid and Hamoud A Al-Malaq
Abstract
In this study, a polyclonal antibody with high avidity and specificity to the potent hypocholesterolaemic agent
rosuvastatin (ROS) has been prepared and used in the development of highly sensitive enzyme-linked
immunosorbent assay (ELISA) for determination of ROS in plasma. ROS was coupled to keyhole limpt hemocyanin
(KLH) and bovine serum albumin (BSA) using carbodiimide reagent. ROS-KLH conjugate was used for immunization
of female 8-weeks old New Zealand white rabbits. The immune response of the rabbits was monitored by direct
ELISA using ROS-BSA immobilized onto microwell plates as a solid phase. The rabbit that showed the highest
antibody titer and avidity to ROS was scarified and its sera were collected. The IgG fraction was isolated and
purified by avidity chromatography on protein A column. The purified antibody showed high avidity to ROS; IC50 =
0.4 ng/ml. The specificity of the antibody for ROS was evaluated by indirect ELISA using various competitors from
the ROS-structural analogues and the therapeutic agents used with ROS in a combination therapy. The proposed
ELISA involved a competitive binding reaction between ROS, in plasma sample, and the immobilized ROS-BSA for
the binding sites on a limited amount of the anti-ROS antibody. The bound anti-ROS antibody was quantified with
horseradish peroxidase-labeled second anti-rabbit IgG antibody (HRP-IgG) and 3,3’,5,5’-tetramethylbenzidine (TMB)
as a substrate for the peroxidase enzyme. The concentration of ROS in the sample was quantified by its ability to
inhibit the binding of the anti-ROS antibody to the immobilized ROS-BSA and subsequently the color intensity in
the assay wells. The assay enabled the determination of ROS in plasma at concentrations as low as 40 pg/ml.
Background
Rosuvastatin (ROS); (3R,5S,6E)-7-[4-((4-fluorophenyl)-6-
(1-methylethyl)-2-[methyl (methylsulphonyl) amino]-5-
pyrimidinyl]-3, 5-dihydroxy-6-heptenoic acid (Figure 1),
is an effective 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase inhibitor and it is widely pre-
scribed in the treatment of patients with hypercholester-
olaemia [1]. ROS is available as Crestor in tablet form
(5, 10, 20, or 40 mg) for oral administration. In clinical
studies, ROS (1-80 mg) produced highly significant
dose-dependent reductions in low-density lipoprotein
cholesterol (up to 65%) and was well tolerated. The
pharmacokinetics of ROS following single and multiple-
dose administration of the drug to healthy volunteers
have been investigated. The absolute oral bioavailability
is greater than 20%, and the elimination half-life is ~ 20
hrs. The reported ROS plasma therapeutic concentration
was 19 ng/ml, after 40 mg-daily dosing. The elimination
of ROS is primarily via the liver. In a clinical trial, ~
90% of the orally administered dose of ROS is recovered
in feces as unchanged drug [2].
Because of the clinical success of ROS, several meth-
ods have been developed for its quantitative determina-
tion in plasma samples. Almost all of these methods are
liquid chromatography [3-9]. These methods involved
tedious steps for the pre-treatment of the samples, pre-
derivatization with critical derivatizing reagents, and use
of expensive detectors (e.g. tandem mass spectrometry)
that are not available in most laboratories. For these
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© 2011 Darwish et alreasons, the development of new alternative analytical
technology for determination of ROS in plasma with
adequate sensitivity, improved simplicity, and lower cost
was seriously needed.
Immunoassays have been widely used in pharmaceuti-
cal and clinical analysis because of their inherent specifi-
city, applicability for a wide range of analytes, high-
throughput, and low cost [10]. ELISA is the most versa-
tile format of the immunoassays. ELISA is remarkably
quick, easily performed, and also offers great sensitivity
when appropriate enzyme labels are used. As well,
ELISA is well suited for the screening of large number
of samples, and the specificity for the analyte of interest
even in multi-component complex sample matrix such
as plasma [10]. The specificity of the antibody to the
analyte of interest is the limiting factor in the validity of
any immunoassay system. In order to establish a specific
and sensitive ELISA for ROS, a specific antibody with
high avidity for ROS was required. The present study
describes, for the first time, the preparation of a polyclo-
nal antibody that can specifically recognizes ROS with
high avidity. The ELISA that has been developed using
this antibody is able to determine ROS in plasma sam-
ples at concentrations as low as 40 pg/ml.
Experimental
Apparatus
Elx808 microplate reader (Bio-Tek Instruments Inc.,
USA). Elx50 microplate washer (Bio-Tek Instruments
Inc., USA). EM-36N microtube shaker (Taitec, Japan).
Biofuge Pico centrifuge (Heraeus Instruments, Ger-
many). Mini/18 incubator (Genlab Ltd., UK). Water pur-
ification system (Milli-Q Labo, Millipore Ltd., Bedford,
USA)
Materials
Rosuvastatin (ROS) was obtained from Biocon India
Ltd., India. Horseradish peroxidase labeled goat anti-
rabbit IgG (HRP-IgG), bovine serum albumin (BSA),
2,4,6-trinitrobenzene sulfonic acid, 1-ethyl-3-(3-dimethy-
laminopropyl) carbodiimide hydrochloride (EDC), and
tween-20 were purchased from Sigma Chemical Co. (St.
Louis, MO, USA). Keyhole limpet hemocyanin (KLH)
was purchased from Novabiochem Co. (La Jolla, CA,
USA). 3,3’,5,5’-Tetramethylbenzidine (TMB) peroxidase
substrate was obtained from Kirkegaard-Perry Labora-
tories (Gaithersburg, MD, USA). ELISA high-binding
microwell plates were a product of Corning/Costar, Inc.
(Cambridge, MA, USA). Centricon-30 filter (Amicon,
Inc., Beverly, MA, USA). BCA reagent for protein assay
and protein A column were obtained from Pierce Bio-
technology Inc. (Rockford, IL, USA).
Procedures
Preparation of ROS-protein conjugates
ROS was conjugated with keyhole limpet hemocyanin
(KLH) and bovine serum albumin (BSA) according to
the method described by Darwish et al [11]. Briefly,
EDC (150 mg) was added to ROS solution (10-ml, 5
mg/ml) in 12.5 mM phosphate buffer (PB) of pH 5, and
the pH of the reaction mixture was maintained at pH 5-
5.5 using 0.01 M HCl for 5 min. Five ml of protein solu-
tion (5 mg/ml, in 50 mM PB of pH 7.2) was added, and
the pH was rapidly adjusted to pH 6.4 and maintained
constant for 90 min. The reaction was left to proceed
overnight in dark at 4°C. The uncojugated ROS was
removed from the ROS-protein conjugates by buffer
exchange using a Centricon-30 filter. Protein content of
each conjugate was determined by BCA reagent kit and
the extent of substitution of free amino groups on the
protein was determined by estimation of free amino
groups on equal amounts of the corresponding protein
which underwent the same experimental treatment and
on protein subjected to the conjugation by the proce-
dure described by Habeeb [12]. The extent of conjuga-
tion = (AROS-Protein/AProtein) × 100; where AROS-Protein
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Figure 1 Preparation of ROS-protein (BSA and KLH) conjugates.
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Page 2 of 8and AProtein were the absorbances obtained from the
reaction of 2,4,6-trinitrobenzene sulfonic acid with ROS-
protein and protein, respectively. The extent of conjuga-
tion was found to be 10.8 and 20.4% of the total amino
group residues on KLH and BSA, respectively.
Immunization of animals and purification of antibody
The immunogen used was ROS-KLH protein conjugate.
Four female 8-weeks old New Zealand white rabbits
were injected subcutaneously with 1 mg of ROS-KLH
emulsified in Freund’s complete adjuvant, divided in dif-
ferent sites for each rabbit. The same immunization pro-
cedure was repeated 6 times with 2-weeks interval,
however incomplete adjuvant was used instead. After 4-
7 days from each immunization, blood samples (~500
μl) were collected and diluted tenfold with PBS. The
diluted blood samples were centrifuged at 10,000 g at 4°
C for 10 min, and the sera (supernatants) were col-
lected. The antibody response in each rabbit was deter-
mined by analysis of the collected antisera by direct
enzyme immunoassay [11]. The rabbit whose diluted
serum gave the highest avidity (lower IC50)t oR O Sw a s
selected as the most appropriate rabbit for collecting its
total serum as as crude anti-ROS polyclonal antibody
sample.
The serum (~20 ml) was kept overnight at 4°C and
then centrifuged at 4°C for 10 min. To 5 ml of the
supernatant, an equal volume of a saturated ammonium
sulfate solution was gradually added and gently mixed.
For complete precipitation of the IgG, the solution was
kept over ice for 3 h. The precipitate was collected by
centrifugation at 10,000 g at 4°C for 30 min. The preci-
pitate was resuspended in 10 ml phosphate buffered sal-
ine (PBS; 137 mM NaCl, 3 mM KCl, and 10 mM
sodium phosphate, pH 7.4) followed by reprecipitation
with ammonium sulfate. After repeating this step three
times, the precipitate was dissolved in 10 ml of PBS.
The produced antibody solution was purified by protein
A column chromatography. One milliliter aliquot of the
solution was mixed with an equal volume of the binding
buffer (1.5 M glycine-NaOH containing 3 M NaCl, pH
8.7) and the mixture was applied to the protein A col-
umn and the eluent was monitored for protein by mea-
suring the absorbance of the eluted fractions at 280 nm.
The column was washed with 50-60 ml of binding buf-
fer, and the bound immunoglobulin was eluted with 0.1
M sodium citrate buffer (pH 3.0). The eluate was col-
lected in 1.5 ml fractions into tubes containing 100 μlo f
1 M Tris-HCl buffer (pH 9.0), and mixed. The pooled
fractions were dialyzed overnight against five changes of
PBS (~ 4 h intervals). The protein content of the dialy-
zate was determined by BCA reagent kit, and used as
the pure anti-ROS antibody sample.
ELISA procedures and data analysis
Aliquot (50 μl) of either ROS-BSA conjugate or BSA
protein solution (5 μg/ml in PBS) was dispensed in each
well of the microwell plate. The plates were incubated
for 2 h at 37°C. The wells were washed with PBS con-
taining 0.05% Tween-20 (PBS-T) and blocked with 200
μl of 3% BSA by incubation at 37°C for 1 h. A 50 μlo f
anti-ROS antibody sample (rabbit serum or purified
IgG) was dispensed in each well and plate was incubated
for 1.5 h at 37°C, then the plates were washed with PBS-
T, and 50 μl of HRP-IgG (1/5,000 in PBS) was added to
each well. After 1.5 h incubation, the plates were
washed with PBS-T and the amount of the bound HRP-
IgG was quantified using TMB microwell substrate.
In competitive ELISA, 50 μl of ROS sample (standard
ROS solution or plasma that have been tenfold diluted
with PBS) was mixed with antibody solution and 50 μl
of the mixture was dispensed into microplate wells that
have been previously coated and blocked. After, the
competition reaction, the signal was generated as above.
T h ed a t aw e r ea c q u i s i t i o n e db yK CJ u n i o rs o f t w a r e
(Bio-Tek Instruments Inc., USA), and transformed to a
four-parameter curve fitting using Slide Write software,
version 5.011 (Advanced Graphics Software, Inc., USA).
Values for IC50 were those that gave the best fit to the
following equation:
A=A 0 −{ (A0 − A1)[ROS]/(IC50 +[ R O S ] )}
Where A is the signal at a definite known concentra-
tion of ROS, A0 is the signal in the absence of ROS, A1
is the signal at the saturating concentration of ROS, and
IC50 is the ROS concentration that produces a 50% inhi-
bition of the signal. The concentrations of ROS in the
samples were then obtained by interpolation on the
standard curve.
Results and discussion
Preparation and characterization of ROS-protein
conjugates
Since ROS is a small molecule, it is not naturally immu-
nogenic. In order to produce antibody specific to ROS,
immunogenic conjugate (immunogen) must be first pre-
pared by its covalently linking to a carrier protein. ROS
contains reactive carboxylic group through which conju-
gation with protein could proceed directly. Although the
introducing of a “spacer group” between the hapten
molecule and the carrier protein usually increases the
specificity of the antibody aimed to be produced [13],
however the reactive COOH group of ROS is ade-
quately spaced (6 carbon atoms) from its aromatic
strong epitopic moieties [14] that is characteristic for
the ROS molecule. Therefore, ROS was directly linked
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reagent (Figure 1).
In order to ascertain the extent to which ROS was
conjugated to the proteins, spectral analysis of the pro-
teins and ROS-protein conjugates were conducted under
the same pH conditions. The apparent molar absorptiv-
ity of ROS-protein conjugates was higher than that of
the unconjugated protein. This hyperchromic effect was
evident for the successful conjugation of the chromo-
phoric ROS molecule with both BSA and KLH. The
extent of conjugation was determined employing BCA
reagent kit for protein assay, and the spectrophotometric
procedures described by Habeeb [12]. The percentages
of ROS residues in ROS-BSA and ROS-KLH conjugates
were found to be 20.4 and 10.8%, respectively.
Preparation and characterization of anti-ROS antibody
Because of the high immunogenicity of KLH [14], ROS-
KLH was selected as immunogen for immunization of
animals and ROS-BSA was selected for immobilization
onto the microwell plates in the ELISA. To monitor the
progress of the immune response of the rabbits and
confirm that they were sufficiently immunized, serum
samples were collected from the rabbits on the fourth to
seventh days after each immunization, and were ana-
lyzed by direct ELISA [11]. As shown in Figure 2A, the
titers of the antisera (indicated by the absorbance
values) increased with the repetitive immunizations,
however, rabbit No. 1 showed weak response and rabbit
No. 4 has been lost after the third immunization. As
well, it was observed that the reactivity of the produced
antibodies to the immobilized protein (BSA) was com-
parable to that before immunization (Figure 2B). These
data indicated the specificity of the raised antibodies to
the ROS residues in the immobilized ROS-BSA, but not
to BSA molecules. The measured small absorbance
values were attributed to the nonspecific binding.
Although, rabbits No. 2 and 3 responded equally to the
repetitive immunizations, however in order to select the
more appropriate one for scarifying and collecting the
total sera, the avidity of their antisera were checked by
competitive ELISA as described above. As shown in
Figure 3A, the serum from rabbit No. 3 has the higher
avidity (lower IC50) for ROS. Therefore this rabbit was
scarified and its total sera were collected as crude anti-
ROS antibody, and it was purified by avidity chromato-
graphy on protein A column.
Figure 2 Monitoring the immune response of rabbits
immunized with ROS-KLH. Micowell plates were coated with ROS-
BSA (panel A) and BSA (panel B). Antiserum samples after different
consecutive immunizations were allowed to bind to the
immobilized antigen (BSA and ROS-BSA). Signals were generated as
described in the Experimental section.
(A)
(B)
Figure 3 Avidity of antisera from rabbits No. 2 (▲)a n dN o .3
(○) for ROS (panel A), and the calibration curve for
determination of ROS in plasma by ELISA (panel B). ROS-BSA
was coated onto the microwell plates. Samples were transferred
into the microwells. Binding reaction was allowed to proceed and
the signals were generated as described in the Experimental
Section.
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In order to determine the optimum limiting concentra-
tion of the purified anti-ROS antibody for effective com-
petition between free ROS (as competitor in the test
sample) and immobilized ROS (ROS-BSA coated onto
the plate wells), titration of anti-ROS versus the solid
phase ROS-BSA was carried. The limited (not saturat-
ing) antibody concentration that gave 1-1.5 absorbance
unit (in the direct ELISA) was 2 μg/ml (Figure 4). This
concentration was used in assessment of the specificity
of the anti-ROS antibody by the competitive ELISA.
Specificity of anti-ROS antibody
The specificity of the antibody was determined by carry-
ing out the competitive assay using various competitors.
These competitors were HMG-Co A reductase inhibi-
tors (atorvastatin, pravastatin, lovastatin, and simvasta-
tin), and various drugs that are administered in
combined therapy with ROS. These drugs were ezeti-
mibe [15], cholestyramine [16], niacin [17], estradiol
[18], fenofibrate [19], candesartan [20], and aspirin [21];
the chemical structures of these competitors are given
in Figure 5. The cross reactivity (CR) was calculated
using the formula: IC50 (ROS)/IC50 (competitor) × 100,
defining IC50 as the concentration of the competitor
that causes 50% reduction of the maximum binding of
anti-ROS antibody to the coating conjugates (i.e. 50% of
the maximum color signal). The values of IC50 that have
been obtained for the competitors, when possible, and
their corresponding cross reactivities are given in Table
1. From these data, it was revealed that pravastatin,
lovastatin and simvastatin, that share the 1,2,7,8,8a-hex-
ahydronaphthyl moiety as a common backbone, did not
cross react with the anti-ROS antibody. On the other
hand, atorvastatin and fluvastatin exhibited small CR (4
and 2%, respectively) with ROS on the anti-ROS
antibody. This feature indicated that the p-fluorophenyl
group (common moiety in all the drugs) is a recogniz-
able epitope for the antibody. This assumption was also
supported by the slight CR (0.8%) that has been exhib-
ited by ezetimibe that has the same moiety in its struc-
ture. The CR that has been exhibited by the HMG-CoA
reductase inhibitors is not problematic in the analysis of
ROS as these drugs are not co-administered simulta-
neously. None of the other competitors (the drugs that
are used in combination therapy with ROS; Figure 5)
showed any CR with ROS in the proposed assay proving
the high specificity of the antibody for ROS, and its pro-
posed ELISA for ROS determination (Table 1).
Competitive ELISA for quantitation of ROS
The calibration curve of ROS using the proposed ELISA
is shown in Figure 3B. This curve was generated using
ROS at concentrations from 10 to 10000 pg/ml, pre-
pared in PBS. The data showed good correlation coeffi-
cient (r = 0.996) on the four-parameter curve fit. The
limit of detection (LOD) of the proposed ELISA, defined
as the lowest ROS concentration significantly different
from zero concentration at 95% confidence limit (mean
of zero ± 4.65 SD) was determined [22]. Based on the
basis of 8 replicate measurements, the limit of detection
in tenfold diluted plasma samples was found to be 40
pg/ml and the working range was 50-1000 pg/ml. This
high sensitivity enables the determination of low thera-
peutic concentrations of ROS in plasma.
The intra-assay precision was assessed at three differ-
ent concentrations (low, middle, and high; Table 2) by
analyzing 8 replicates of each sample in a single run and
the inter-assay precision was assessed by analyzing the
same sample, as duplicates, in 4 separate runs. Accord-
ing to the recommendation of immunoassay validation
[23], the assay gave satisfactory results as the values of
relative standard deviations did not exceed 5% (Table 2).
Studying the plasma matrix effect was required since
the proposed assay was designed for quantitation of
ROS in plasma. ROS-free plasma sample was serially
diluted into PBS and each dilution was spiked with 200
pg/ml of ROS standard. The spiked samples were then
analyzed by the proposed assay to investigate the feasi-
bility of the assay. Acceptable recovery values [23] were
obtained when plasma samples were diluted 10-fold
with PBS. Therefore, plasma samples should be 10-fold
diluted with PBS in order to avoid the possible false-
positive analytical results. It is worth to mention that
the high sensitivity of the assay (LOD was 40 pg/ml)
allowed the high dilution of a clinical specimen (19 ng/
ml after 40 mg dosing) to attain the ROS concentrations
in the working range of the assay.
The accuracy of the method was checked by recovery
studies. ROS-free plasma samples (50 μl) were spiked
Figure 4 Titration of the purified anti-ROS IgG antibody versus
immobilized ROS-BSA conjugate.
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Page 5 of 8with 50 μl of varying concentrations of ROS, and the
spiked samples were mixed with 400 μlo fP B St og i v e
final concentrations of 50-800 pg/ml. The samples were
subjected to the analysis by the competitive ELISA, and
the recovery values were calculated. The analytical
recovery values were 98.9-105.0 ± 1.89-4.38% (Table 2).
This indicated the accuracy of the proposed method for
determination of ROS in plasma samples, and absence
of endogenous interfering substances in the plasma
samples.
In order to compare the proposed ELISA with HPLC,
plasma samples were spiked with ROS at known
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method. These concentrations were 0.001-0.05 μg/ml.
These concentrations were selected based on the sensi-
tivity of the HPLC method. As the proposed ELISA has
higher sensitivity, the same samples were diluted with
PBS to make their concentrations within the working
range of the proposed ELISA method. The concentra-
tions measured by HPLC were plotted versus their cor-
responding values that have been determined by the
proposed ELISA. Regression analysis of the results was
performed, and the results revealed the good agreement
between the two methods: EIA = 0.00198 + 0.8768
HPLC (r = 0.988).
Conclusions
T h ep r e s e n ts t u d yd e s c r i b e dt h ep r e p a r a t i o no fah i g h l y
specific polyclonal antibody against ROS. The antibody
recognizes ROS with high avidity. The high specificity
and avidity of the produced antibody enabled the devel-
opment of highly specific and sensitive ELISA for the
accurate determination of ROS in plasma without pre-
treatment at concentrations as low as 40 pg/ml. The
assay produces a colored read-out, thus only a colori-
metric plate reader is required. The entire protocol of
t h ep r e s e n ta s s a yi sv e r ye a s yt op e r f o r mi na9 6 - w e l l
plate and permits an operator to analyze a batch of 200
samples per day when uses a pre-coated plates facilitat-
ing the processing of large number of samples. The pro-
posed ELISA is expected to contribute to the
pharmacokinetic studies of ROS as an effective alterna-
tive to the existing costive and instrument-intensive
chromatographic technologies.
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